source
- Invivyd reports Phase 3 LIBERTY trial shows its low-dose antibody VYD2311 is safer and better tolerated than Pfizer’s Covid vaccineInvivyd, a small biotech focused on an injectable monoclonal antibody as an alternative to Covid vaccines, has released new data from its Phase 3 LIBERTY study. The trial compared the company’s ca…
- AI system Claude decodes a whole genome in 30 minutes, sparking call for result standardsThe author, a Stanford physician‑scientist, used the AI model Claude to analyze his entire genome in roughly half an hour, at a cost of about five dollars. The rapid analysis produced a detailed re…